| Medical and Health Sciences | Lifetime | 404 | NL 7 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 322 | NL 6 | 99.93 |
| Physical Therapy, Sports Therapy and Rehabilitation | Lifetime | 5 | NL 1 | 99.94 |
| Clinical Neurology | Lifetime | 22 | NL 1 | 99.92 |
| Psychiatry and Mental health | Lifetime | 344 | NL 8 | 98.90 |
| Neuroscience of Neurology | Lifetime | 468 | NL 8 | 96.26 |
| Clinical Neurology | 2021-2025 | 4 | NL 1 | 99.85 |
| Physical Therapy, Sports Therapy and Rehabilitation | 2021-2025 | 57 | NL 3 | 97.02 |
| Cognitive Neuroscience | 2021-2025 | 447 | NL 21 | 91.67 |
| Psychiatry and Mental health | 2021-2025 | 328 | NL 8 | 91.72 |
| Cellular and Molecular Neuroscience | 2021-2025 | 214 | NL 5 | 83.29 |
| Balance, Gait, and Falls Prevention | Lifetime | 4 | NL 1 | 99.91 |
| Cerebral Palsy and Movement Disorders | Lifetime | 5 | NL 1 | 99.90 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 20 | NL 1 | 99.89 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 26 | NL 2 | 99.74 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 30 | NL 1 | 99.81 |
| Dysphagia Assessment and Management | Lifetime | 69 | NL 8 | 98.79 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 14 | NL 1 | 98.94 |
| Chronic Disease Management Strategies | Lifetime | 169 | NL 14 | 98.59 |
| Genetic Neurodegenerative Diseases | Lifetime | 226 | NL 5 | 98.59 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 627 | NL 45 | 98.52 |
| Restless Legs Syndrome Research | Lifetime | 48 | NL 1 | 98.31 |
| Long-Term Effects of COVID-19 | Lifetime | 481 | NL 11 | 96.40 |
| Muscle activation and electromyography studies | Lifetime | 529 | NL 26 | 97.91 |
| Transcranial Magnetic Stimulation Studies | Lifetime | 336 | NL 7 | 97.18 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 607 | NL 20 | 94.93 |
| Nuclear Receptors and Signaling | Lifetime | 403 | NL 6 | 94.72 |
| Neurological diseases and metabolism | Lifetime | 510 | NL 8 | 94.36 |
| Telemedicine and Telehealth Implementation | Lifetime | 450 | NL 7 | 92.29 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 524 | NL 20 | 92.37 |
| Assistive Technology in Communication and Mobility | Lifetime | 361 | NL 9 | 91.95 |
| Motor Control and Adaptation | Lifetime | 860 | NL 47 | 93.46 |
| Neurological and metabolic disorders | Lifetime | 642 | NL 14 | 90.13 |
| Effects of Vibration on Health | Lifetime | 930 | NL 38 | 83.79 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 2 | NL 1 | 99.81 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 8 | NL 1 | 99.70 |
| Cerebral Palsy and Movement Disorders | 2021-2025 | 16 | NL 1 | 98.62 |
| Balance, Gait, and Falls Prevention | 2021-2025 | 19 | NL 3 | 98.32 |
| Botulinum Toxin and Related Neurological Disorders | 2021-2025 | 85 | NL 2 | 95.96 |
| Pesticide Exposure and Toxicity | 2021-2025 | 41 | NL 3 | 94.99 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 153 | NL 7 | 94.18 |
| Autism Spectrum Disorder Research | 2021-2025 | 315 | NL 6 | 94.53 |
| Neurological diseases and metabolism | 2021-2025 | 61 | NL 2 | 92.39 |
| Dysphagia Assessment and Management | 2021-2025 | 402 | NL 11 | 87.88 |
| Voice and Speech Disorders | 2021-2025 | 625 | NL 11 | 79.80 |
| Lysosomal Storage Disorders Research | 2021-2025 | 734 | NL 33 | 76.02 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 770 | NL 32 | 68.30 |
| Restless Legs Syndrome Research | 2021-2025 | 356 | NL 2 | 65.77 |
| Parkinson's Disease and Spinal Disorders | 2021-2025 | 212 | NL 6 | 65.14 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 402 | NL 1 | 55.76 |
| Music Therapy and Health | 2021-2025 | 747 | NL 25 | 56.53 |
